Aerie Pharmaceuticals Acquires Drug Delivery Assets From Envisia

Irvine-based Aerie Pharmaceuticals, which is developing treatments for patients with glaucoma and other eye diseases, said this morning that it has acquired a number of drug delivery assets from Envisia Therapeutics. According to Aerie Pharmaceuticals, it is paying $25M in a combination of cash and common stock for the technology. The technology involved is a system capable of creating precisely engineered sustained release of pharmaceuticals, according to Aerie, which it says it will use to accelerate the advancement of its pipeline.